These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1128 related items for PubMed ID: 22534171

  • 1. Opposite regulation by PI3K/Akt and MAPK/ERK pathways of tissue factor expression, cell-associated procoagulant activity and invasiveness in MDA-MB-231 cells.
    Hu C, Huang L, Gest C, Xi X, Janin A, Soria C, Li H, Lu H.
    J Hematol Oncol; 2012 Jul 11; 5():16. PubMed ID: 22534171
    [Abstract] [Full Text] [Related]

  • 2. MicroRNA-29b Inhibits Angiogenesis by Targeting VEGFA through the MAPK/ERK and PI3K/Akt Signaling Pathways in Endometrial Carcinoma.
    Chen HX, Xu XX, Tan BZ, Zhang Z, Zhou XD.
    Cell Physiol Biochem; 2017 Jul 11; 41(3):933-946. PubMed ID: 28222438
    [Abstract] [Full Text] [Related]

  • 3. Relevance of mitogen activated protein kinase (MAPK) and phosphotidylinositol-3-kinase/protein kinase B (PI3K/PKB) pathways to induction of apoptosis by curcumin in breast cells.
    Squires MS, Hudson EA, Howells L, Sale S, Houghton CE, Jones JL, Fox LH, Dickens M, Prigent SA, Manson MM.
    Biochem Pharmacol; 2003 Feb 01; 65(3):361-76. PubMed ID: 12527329
    [Abstract] [Full Text] [Related]

  • 4. Platycodin D inhibits migration, invasion, and growth of MDA-MB-231 human breast cancer cells via suppression of EGFR-mediated Akt and MAPK pathways.
    Chun J, Kim YS.
    Chem Biol Interact; 2013 Oct 05; 205(3):212-21. PubMed ID: 23867902
    [Abstract] [Full Text] [Related]

  • 5. The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib.
    Normanno N, De Luca A, Maiello MR, Campiglio M, Napolitano M, Mancino M, Carotenuto A, Viglietto G, Menard S.
    J Cell Physiol; 2006 May 05; 207(2):420-7. PubMed ID: 16419029
    [Abstract] [Full Text] [Related]

  • 6. Activation of tissue-factor gene expression in breast carcinoma cells by stimulation of the RAF-ERK signaling pathway.
    Zhou JN, Ljungdahl S, Shoshan MC, Swedenborg J, Linder S.
    Mol Carcinog; 1998 Apr 05; 21(4):234-43. PubMed ID: 9585253
    [Abstract] [Full Text] [Related]

  • 7. PI3K/Akt and MAPK/ERK1/2 signaling pathways are involved in IGF-1-induced VEGF-C upregulation in breast cancer.
    Zhu C, Qi X, Chen Y, Sun B, Dai Y, Gu Y.
    J Cancer Res Clin Oncol; 2011 Nov 05; 137(11):1587-94. PubMed ID: 21904903
    [Abstract] [Full Text] [Related]

  • 8. Simvastatin-induced breast cancer cell death and deactivation of PI3K/Akt and MAPK/ERK signalling are reversed by metabolic products of the mevalonate pathway.
    Wang T, Seah S, Loh X, Chan CW, Hartman M, Goh BC, Lee SC.
    Oncotarget; 2016 Jan 19; 7(3):2532-44. PubMed ID: 26565813
    [Abstract] [Full Text] [Related]

  • 9. Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma.
    Wong MH, Xue A, Julovi SM, Pavlakis N, Samra JS, Hugh TJ, Gill AJ, Peters L, Baxter RC, Smith RC.
    Clin Cancer Res; 2014 Aug 01; 20(15):4047-58. PubMed ID: 24895459
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Overexpression of the miR-141/200c cluster promotes the migratory and invasive ability of triple-negative breast cancer cells through the activation of the FAK and PI3K/AKT signaling pathways by secreting VEGF-A.
    Choi SK, Kim HS, Jin T, Hwang EH, Jung M, Moon WK.
    BMC Cancer; 2016 Aug 02; 16():570. PubMed ID: 27484639
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Inhibition of EGF/EGFR activation with naphtho[1,2-b]furan-4,5-dione blocks migration and invasion of MDA-MB-231 cells.
    Hsieh CY, Tsai PC, Tseng CH, Chen YL, Chang LS, Lin SR.
    Toxicol In Vitro; 2013 Feb 02; 27(1):1-10. PubMed ID: 23064031
    [Abstract] [Full Text] [Related]

  • 14. Phosphoinositide 3-kinase targeting by the beta galactoside binding protein cytokine negates akt gene expression and leads aggressive breast cancer cells to apoptotic death.
    Wells V, Mallucci L.
    Breast Cancer Res; 2009 Feb 02; 11(1):R2. PubMed ID: 19133120
    [Abstract] [Full Text] [Related]

  • 15. Antimetastatic effect and mechanism of ovatodiolide in MDA-MB-231 human breast cancer cells.
    Lin KL, Tsai PC, Hsieh CY, Chang LS, Lin SR.
    Chem Biol Interact; 2011 Nov 15; 194(2-3):148-58. PubMed ID: 22033475
    [Abstract] [Full Text] [Related]

  • 16. ADAM17 promotes breast cancer cell malignant phenotype through EGFR-PI3K-AKT activation.
    Zheng X, Jiang F, Katakowski M, Zhang ZG, Lu QE, Chopp M.
    Cancer Biol Ther; 2009 Jun 15; 8(11):1045-54. PubMed ID: 19395875
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of either phosphatidylinositol 3-kinase/Akt or the mitogen/extracellular-regulated kinase, MEK/ERK, signaling pathways suppress growth of breast cancer cell lines, but MEK/ERK signaling is critical for cell survival.
    Ripple MO, Kalmadi S, Eastman A.
    Breast Cancer Res Treat; 2005 Sep 15; 93(2):177-88. PubMed ID: 16187238
    [Abstract] [Full Text] [Related]

  • 18. AMR-Me inhibits PI3K/Akt signaling in hormone-dependent MCF-7 breast cancer cells and inactivates NF-κB in hormone-independent MDA-MB-231 cells.
    Rabi T, Huwiler A, Zangemeister-Wittke U.
    Mol Carcinog; 2014 Jul 15; 53(7):578-88. PubMed ID: 23475563
    [Abstract] [Full Text] [Related]

  • 19. TNF-alpha induces MMP-9 expression via activation of Src/EGFR, PDGFR/PI3K/Akt cascade and promotion of NF-kappaB/p300 binding in human tracheal smooth muscle cells.
    Lee CW, Lin CC, Lin WN, Liang KC, Luo SF, Wu CB, Wang SW, Yang CM.
    Am J Physiol Lung Cell Mol Physiol; 2007 Mar 15; 292(3):L799-812. PubMed ID: 17158602
    [Abstract] [Full Text] [Related]

  • 20. Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways.
    Yuen HF, Chan KK, Grills C, Murray JT, Platt-Higgins A, Eldin OS, O'Byrne K, Janne P, Fennell DA, Johnston PG, Rudland PS, El-Tanani M.
    Clin Cancer Res; 2012 Jan 15; 18(2):380-91. PubMed ID: 22090358
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 57.